Fig. 6

Effect of osimertinib combined with pemetrexed or cisplatin on cell proliferation and cell death induction in PC9 and HCC827 cell line. a PC9 and HCC827 cells were treated with 50 nM osimertinib, 50 nM pemetrexed or 500 nM cisplatin on the basis of schedules indicated in Fig. 4a. After 12 days crystal violet assay was performed and absorbance was measured at 570 nm. Results are representative of three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 vs osimertinib; one-way analysis of variance followed by Bonferroni’s post-test. b PC9 and HCC827 cells were treated with 50 nM osimertinib, 50 nM pemetrexed or 500 nM cisplatin on the basis of the schedules indicated in Fig. 4b. At the end of the treatment period cell death was quantified by fluorescence microscopy analysis on Hoechst 33342 and propidium iodide-stained cells. Results represent the mean (± standard deviation SD) of three independent experiments. ****p < 0.001 vs control; #p < 0.05, ##p < 0.01, ###p < 0.001 vs osimertinib; one-way analysis of variance followed by Bonferroni’s post-test